First generic copy of Roche’s Tamiflu hits US market

pharmafile | December 12, 2016 | News story | Sales and Marketing |  Alvogen, Roche, Tamiflu 

Drugmaker Alvogen has released the first generic version of Roche’s flu medication Tamiflu (oseltamivir) in the US, where it expects to save the healthcare system as much as $500 million.

Developed in cooperation with India-based Natco Pharma, the drug is available in three strengths: 30mg, 45mg and 75mg.

“The launch of oseltamivir phosphate is great news for US patients, who will finally have access to a more affordable alternative to Tamiflu,” commented Robert Wessman, chairman and CEO of Alvogen. “It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”

Advertisement

While it accounts for a relatively small portion of Roche’s overall revenue, Tamiflu managed to earn $3 billion in the wake of the H1N1 swine flu outbreak of 2009.

According to IMS Health, Alvogen’s drug portfolio has reported current brand sales in excess of $25 billion.

Matt Fellows

Related Content

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content